HER2

Summary

Gene Symbol: HER2
Description: erb-b2 receptor tyrosine kinase 2
Alias: CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, receptor tyrosine-protein kinase erbB-2, c-erb B2/neu protein, herstatin, human epidermal growth factor receptor 2, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Species: human
Products:     HER2

Top Publications

  1. Lamy P, Fina F, Bascoul Mollevi C, Laberenne A, Martin P, Ouafik L, et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011;13:R15 pubmed publisher
    b>Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers represent a tumor subtype with chromosome 17q rearrangements that lead to frequent gene amplifications...
  2. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol. 2010;49:767-75 pubmed publisher
    ..Further studies are required to reinvestigate these findings and evaluate the functional significance. ..
  3. Saglam S, Suzme R, Gurdol F. Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients. Int J Biol Markers. 2009;24:142-6 pubmed
    ..Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, ..
  4. Ingold Heppner B, Behrens H, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111:1977-84 pubmed publisher
    Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives...
  5. Lerdrup M, Bruun S, Grandal M, Roepstorff K, Kristensen M, Hommelgaard A, et al. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell. 2007;18:3656-66 pubmed
    ..Altogether, we suggest that geldanamycin leads to C-terminal cleavage of ErbB2, which releases the receptor from a retention mechanism and causes endocytosis and lysosomal degradation of ErbB2. ..
  6. Fijołek J, Wiatr E, Rowinska Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers. 2006;21:81-7 pubmed
    The aim of the study was to investigate a relation between p53 and HER2/neu expression in resected lung tumors and the response of those tumors to neoadjuvant chemotherapy...
  7. Ghayad S, Vendrell J, Ben Larbi S, Dumontet C, Bieche I, Cohen P. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545-62 pubmed publisher
    ..In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients. ..
  8. Haslekås C, Breen K, Pedersen K, Johannessen L, Stang E, Madshus I. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell. 2005;16:5832-42 pubmed
  9. Lang J, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009;113:501-7 pubmed publisher
    ..0 CTC per CTC positive patient (range 1-22). HER2 status was the sole primary tumor characteristic that reliably predicted the presence of CTCs (P = 0...

More Information

Publications425 found, 100 shown here

  1. Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers. 2010;25:126-35 pubmed
    ..The present study was conducted to clarify the diagnostic and prognostic significance of TNF-alpha and its combination with HER-2 Ile655Val SNP in breast cancer...
  2. Sun T, Aceto N, Meerbrey K, Kessler J, Zhou C, Migliaccio I, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144:703-18 pubmed publisher
    ..PTPN12 suppresses transformation by interacting with and inhibiting multiple oncogenic tyrosine kinases, including HER2 and EGFR...
  3. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras J, Pichon M. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 2004;19:14-22 pubmed
    ..To determine the clinical correlations and prognostic value of serum HER-2 (sHER-2) before and after primary breast cancer treatment...
  4. Kang L, Guo Y, Zhang X, Meng J, Wang Z. A positive cross-regulation of HER2 and ER-?36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol. 2011;127:262-8 pubmed publisher
    ..in these cells using the shRNA method diminished their responsiveness to estrogen and significantly down-regulated HER2 expression...
  5. Park D, Kang M, Oh S, Kim H, Cho Y, Sohn C, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2007;22:491-7 pubmed
    The HER-2/neu protein is intimately involved with normal cell proliferation and tissue growth, as it is extensively homologous and is related to the epidermal growth factor receptor...
  6. Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther. 2010;9:1198-207 pubmed publisher
    Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome...
  7. Wallasch C, Weiss F, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995;14:4267-75 pubmed
    Amplification and/or overexpression of HER2/neu and HER3 genes have been implicated in the development of cancer in humans...
  8. Sahlberg K, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due E, et al. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol. 2013;7:392-401 pubmed publisher
    About 20% of breast cancers are characterized by amplification and overexpression of the HER2 oncogene...
  9. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124:403-12 pubmed publisher
    There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients...
  10. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nistico C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011;17:2055-64 pubmed publisher
    To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression...
  11. Grabsch H, Sivakumar S, Gray S, Gabbert H, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65 pubmed publisher
    ..Existing data on HER2 expression and its clinical relevance in GC are still limited and controversial...
  12. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun. 2011;411:804-8 pubmed publisher
    Gene amplification and protein overexpression of erbB2 (Her2/neu) has been observed in approximately 20-30% of breast cancers...
  13. Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17:661-5 pubmed publisher
    The aim of this retrospective study was to examine the influence of HER2 status on outcome in breast cancer patients following whole brain radiotherapy (WBRT) for cerebral metastases...
  14. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009;27:1685-93 pubmed publisher
    Trastuzumab is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2)...
  15. Begnami M, Fukuda E, Fregnani J, Nonogaki S, Montagnini A, da Costa W, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030-6 pubmed publisher
    The human epidermal growth factor receptor (HER) family consists of four members: ErbB-1 (HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)...
  16. Soysal S, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, et al. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer. 2013;108:1480-7 pubmed publisher
    ..intrinsic subtypes, EpCAM expression was associated with an unfavourable prognosis in the basal-like and luminal B HER2(+) subtypes but associated with a favourable prognosis in the HER2 subtype...
  17. Tong S, Ha S, Ki K, Lee J, Lee S, Lee K, et al. The effects of obesity and HER-2 polymorphisms as risk factors for endometrial cancer in Korean women. BJOG. 2009;116:1046-52 pubmed publisher
    ..Endometrial cancer risk increased significantly in proportion to BMI. However, HER-2 polymorphism did not affect significantly on the risk of endometrial cancer. ..
  18. Zhan N, Dong W, Tang Y, Wang Z, Xiong C. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012;29:933-40 pubmed publisher
    The HER2 gene, which is located on chromosomes 17, is a therapeutic target for cancer. Amplification of HER2 has been described in several tumor types...
  19. Choi J, Han H, Lee H, Lee O, Kim J, Lim S, et al. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia. Onkologie. 2011;34:621-4 pubmed publisher
    Trastuzumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2), has been shown to be active against metastatic gastric cancers that overexpress HER2...
  20. Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-25 pubmed
    The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor...
  21. Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson N, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45:590-6 pubmed
    The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer...
  22. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol. 2009;131:678-82 pubmed publisher
    We evaluated intratumoral heterogeneity of 30 ductal breast carcinomas with HER2/neu amplification, scored by the American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) criteria, and 3+ immunoexpression...
  23. Menard S, Casalini P, Campiglio M, Pupa S, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965-78 pubmed
    b>HER2 (human epidermal growth factor receptor-2; also known as erbB2) and its relatives HER1 (epidermal growth factor receptor; EGFR), HER3 and HER4 belong to the HER family of receptor tyrosine kinases...
  24. Ding Y, Liu Z, Desai S, Zhao Y, Liu H, Pannell L, et al. Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun. 2012;3:1271 pubmed publisher
    ..Our study provides a novel perspective on the metabolic regulatory function of ErbB2 and reveals that mtErbB2 has an important role in the regulation of cellular metabolism and cancer cell resistance to therapeutics. ..
  25. Marks J, McLellan M, Zakowski M, Lash A, Kasai Y, Broderick S, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE. 2007;2:e426 pubmed
    ..e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS...
  26. Scott G, Marx C, Berger C, Saunders L, Verdin E, Schafer S, et al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res. 2008;6:1250-8 pubmed publisher
  27. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74:139-44 pubmed publisher
    Activating mutation in the kinase domain of the human EGF receptor 2 (HER2) gene (also known as ERBB2 or neu) is reported to be present in a small fraction of lung adenocarcinomas...
  28. Xia W, Petricoin E, Zhao S, Liu L, Osada T, Cheng Q, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013;15:R85 pubmed
    The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted tumors...
  29. Siziopikou K, Khan S. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol. 2005;13:14-8 pubmed
    The protein product of the HER2 oncogene is overexpressed in an estimated 25 to 30% of breast carcinomas and is considered an indicator of poor clinical outcome...
  30. Susini T, Bussani C, Marini G, Nori J, Olivieri S, Molino C, et al. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. Gynecol Oncol. 2010;116:234-9 pubmed publisher
    Knowledge of HER-2/neu status is mandatory to identify breast cancer patients amenable to trastuzumab treatment...
  31. McDonagh C, Huhalov A, Harms B, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 2012;11:582-93 pubmed publisher
    ..MM-111 can be rationally combined with trastuzumab or lapatinib for increased antitumor activity and may in the future complement existing ErbB2-directed therapies to treat resistant tumors or deter relapse. ..
  32. Di Leo A, Desmedt C, Bartlett J, Piette F, Ejlertsen B, Pritchard K, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134-42 pubmed publisher
    ..We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast ..
  33. An H, Kim N, Oh D, Kim S, Park M, Jung M, et al. Her2 genotype and breast cancer progression in Korean women. Pathol Int. 2005;55:48-52 pubmed
    The amplification and overexpression of Her2 proto-oncogene have been found to be associated with the development and progression of human breast cancer...
  34. Tikhomirov O, Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 2003;63:39-43 pubmed
    The ansamycin antibiotic geldanamycin (GA) induces the intracellular degradation of ErbB-2/neu. Degradation of ErbB-2 proceeds through cleavage(s) within the kinase domain, resulting in the formation of a 135 kDa ectodomain fragment and ..
  35. Geradts J, Bean S, Bentley R, Barry W. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010;28:969-77 pubmed publisher
    ..was correlated with six pathobiologic features: estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status, and the three components of the Nottingham tumor grade...
  36. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508-23 pubmed publisher
    ..Genotype-response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases...
  37. Zhao Y, Zhou M, Liu H, Ding Y, Khong H, Yu D, et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009;28:3689-701 pubmed publisher
    ..This pathway may have a major role in regulating glucose metabolism in breast cancer cells. These novel findings have important implications for the design of new approaches to target ErbB2-overexpressing breast cancers. ..
  38. Moulder S, Yakes F, Muthuswamy S, Bianco R, Simpson J, Arteaga C. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887-95 pubmed
    Aberrrant signaling by the epidermal growth factor receptor [EGFR (HER1, erbB1)] and/or HER2/neu tyrosine kinases is present in a cohort of breast carcinomas...
  39. Penuel E, Akita R, Sliwkowski M. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem. 2002;277:28468-73 pubmed
    ..A well characterized mutant of the rodent ortholog neu involves substitution of glutamate for valine within the transmembrane domain...
  40. Leary A, Hanna W, van de Vijver M, Penault Llorca F, Ruschoff J, Osamura R, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009;27:1694-705 pubmed publisher
    ..This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer. ..
  41. Wu S, Cheng T, Chen W, Shyu H, Ko C, Huang H, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol. 2010;177:3145-58 pubmed publisher
    ..In summary, our data indicate that ErbB-2 signaling via the phosphatidylinositol 3-kinase pathway results in up-regulated matriptase zymogen activity, which contributes to PCa cell invasion. ..
  42. Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, et al. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol Cell Biol. 2012;32:3913-24 pubmed publisher
    ..Furthermore, we showed that the receptor tyrosine kinase ErbB2/HER2 is a direct substrate of PTPRO and that loss of PTPRO increased ErbB2-induced cell proliferation and transformation,..
  43. Khan A, King B, Smith B, Smith G, Digiovanna M, Carter D, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002;8:540-8 pubmed
    The role of HER-2/neu in squamous cell carcinoma (SCC) of the head and neck is not well defined...
  44. Bargmann C, Hung M, Weinberg R. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226-30 pubmed
    The neu oncogene is repeatedly activated in neuro- and glioblastomas derived by transplacental mutagenesis of the BDIX strain of rat with ethylnitrosourea...
  45. Adam L, Vadlamudi R, Kondapaka S, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998;273:28238-46 pubmed
    ..We also demonstrated that HRG stimulation promoted physical interactions between PAK1, actin, and human epidermal growth factor receptor 2 (HER2) receptors, and these interactions were dependent on the activation of PI-3 kinase...
  46. Seol H, Lee H, Choi Y, Lee H, Kim Y, Kim J, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25:938-48 pubmed publisher
    Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene amplification has been reported to occur with variable frequencies in breast cancers...
  47. Morrison L, Jewell S, Usha L, Blondin B, Rao R, Tabesh B, et al. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007;46:397-405 pubmed
    ..These results suggest that patient selection for trastuzumab may be improved by considering ERBB2 amplicon size and genomic status of the 1q25, PTGS2, and centromere 10 loci. ..
  48. Lee Hoeflich S, Crocker L, Yao E, Pham T, Munroe X, Hoeflich K, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878-87 pubmed publisher
    Epidermal growth factor receptor (EGFR) and HER3 each form heterodimers with HER2 and have independently been implicated as key coreceptors that drive HER2-amplified breast cancer...
  49. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown A, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-704 pubmed publisher
    b>Human epidermal growth factor receptor 2 gene (HER2) is associated with a poorer outcome in node-positive breast cancer, but the results are conflicting in node-negative disease...
  50. Mittendorf E, Tucker S, McKenzie T, Qiao N, Akli S, Biernacka A, et al. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010;29:3896-907 pubmed publisher
    b>HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two...
  51. Kruger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102:514-8 pubmed
    The HER2 (c-erbB-2) receptor is overexpressed in a variety of human malignant tumors and, in breast carcinoma, has been identified as a target for anti-HER2-directed therapy with the monoclonal antibody (MAb) trastuzumab...
  52. Hendriks B, Opresko L, Wiley H, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem. 2003;278:23343-51 pubmed
    ..Many cell types express multiple EGFR family members (including EGFR, HER2, HER3, and/or HER4) that interact to form an array of homo- and heterodimers...
  53. Tubbs R, Barlow W, Budd G, Swain E, Porter P, Gown A, et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009;27:3881-6 pubmed publisher
    ..We determined the status of the HER2 and TOP2A genes in a large cohort of breast cancer patients treated with adjuvant doxorubicin (A) and ..
  54. Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009;4:1066-74 pubmed publisher
    ..In the five NSCLC cell lines, expressions of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and hepatocyte growth factor receptor (c-Met) in PC-9 cells; of HER2 and c-Met in ..
  55. Helmke B, Zahel T, Breinig M, Schirmacher P, Aulmann S, Kern M. Her2 overexpression is a rare event in anorectal melanoma. Melanoma Res. 2010;20:431-4 pubmed publisher
    ..Tyrosin kinase receptors such as Her2 and EGFR have been awarded a large role in this context...
  56. Epis M, Barker A, Giles K, Beveridge D, Leedman P. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem. 2011;286:41442-54 pubmed publisher
  57. Frank B, Hemminki K, Wirtenberger M, Bermejo J, Bugert P, Klaes R, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005;26:643-7 pubmed
    Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20-30% of breast cancers involving poor prognosis. Genetic alterations within ERBB2 have been shown to induce carcinogenesis and metastasis...
  58. Kim Y, Won Y, Park K, Song B, Kim J, Oh S, et al. Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci. 2008;23:414-20 pubmed publisher
    It is well known that the amplification of the HER2 gene is closely associated with poor prognosis of breast cancer. However, there is controversy about the clinical significance of HER2 according to lymph node status in breast cancer...
  59. Kim K, Koh Y, Chang H, Kim T, Yook J, Kim B, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833-40 pubmed publisher
    Recent advances in molecular targeted therapy have identified HER2 as an important target for anti-cancer therapy in gastric cancer (GC)...
  60. Liu P, Cleveland T, Bouyain S, Byrne P, Longo P, Leahy D. A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci U S A. 2012;109:10861-6 pubmed publisher
    ..of epidermal growth factor (EGF) binding to EGFR and the behavior of the ligandless EGFR homolog ErbB2/HER2, however...
  61. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene. 2005;24:4540-8 pubmed
    ..Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents. ..
  62. Millikan R, Hummer A, Wolff M, Hishida A, Begg C. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat. 2005;89:309-12 pubmed
    ..epidemiologic studies show increased breast cancer risk for carriers of the Val-allele at codon 655 of the HER2 gene...
  63. Cox D, Hankinson S, Hunter D. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics. 2005;15:447-50 pubmed
    The erbB2 (HER2/neu) gene is found amplified in tumours. A single nucleotide polymorphism at codon 655 (Ile655Val) has been studied in a number of case-control studies with respect to breast cancer risk, with conflicting results...
  64. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85-9 pubmed publisher
    A fraction of lung adenocarcinomas harbor activating mutations in the HER2 kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly unselected patients...
  65. Ren Z, Schaefer T. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem. 2002;277:38486-93 pubmed
  66. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230-4 pubmed
    ..The c-erb-B-2 gene is conserved in vertebrates and it has been suggested that the neu gene, detected in a series of rat neuro/glioblastomas, is, in fact, the rat c-erb-B-2 gene...
  67. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, et al. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON. 2008;13:409-13 pubmed
    The extracellular domain (ECD) of the HER2 receptor is proposed as a real-time marker of HER2-positive breast cancer (BC). In this study, ECD-HER2 levels were compared with standard clinical and pathological prognostic factors...
  68. Yu G, Chen Y, Wang J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol. 2009;135:1331-9 pubmed publisher
    Growth factor receptor-bound 2 (Grb2)-mediated HER2 signaling is thought to play a critical role in gastric cancer development, progression and metastasis. However, little is known about their expression in gastric cancer...
  69. Pontier S, Huck L, White D, Rayment J, Sanguin Gendreau V, Hennessy B, et al. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene. 2010;29:3374-85 pubmed publisher
    ..These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction. ..
  70. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;17:895-904 pubmed
    ..Overexpression of HER-2 and EGFR were observed in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification. ..
  71. Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E, et al. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma. 2007;54:365-73 pubmed
    Alterations of c-erbB-2 (neu or HER-2) proto-oncogene have been associated with carcinogenesis and poor prognosis of breast cancer...
  72. Beguelin W, Díaz Flaqué M, Proietti C, Cayrol F, Rivas M, Tkach M, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010;30:5456-72 pubmed publisher
    ..Our findings reveal a novel therapeutic intervention for PR- and ErbB-2-positive breast tumors via the specific blockage of ErbB-2 nuclear translocation...
  73. Hartman Z, Zhao H, Agazie Y. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013;32:4169-80 pubmed publisher
    One of the causes of breast cancer is overexpression of the human epidermal growth factor receptor 2 (HER2)...
  74. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A. 2002;99:12847-52 pubmed
    ..These data describe a previously unrecognized pathway, amenable to pharmacologic manipulation, that mediates ErbB2 stability. ..
  75. Fabi A, Metro G, Di Benedetto A, Nistico C, Vici P, Melucci E, et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology. 2010;78:141-9 pubmed publisher
    ..We investigated the clinical impact of the expression of PTEN, p-Akt and PI3K in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab-based therapies...
  76. Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat. 2010;123:437-45 pubmed publisher
    ..Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial...
  77. Ueda M, Hung Y, Terai Y, Saito J, Nunobiki O, Noda S, et al. HER-2 codon 655 polymorphism in cervical carcinogenesis. Int J Gynecol Cancer. 2006;16:325-8 pubmed
    ..These results suggest that the HER-2 polymorphism at codon 655 in cervical cell samples is unlikely to be associated with HPV status and the onset of cervical cancer in a Japanese population. ..
  78. Ciravolo V, Huber V, Ghedini G, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227:658-67 pubmed publisher
    ..We characterized exosomes constitutively secreted by HER2-overexpressing breast carcinoma cell lines and analyzed in vitro and in vivo their potential role in interfering ..
  79. Li M, Wang Y, Hung M, Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer. Int J Cancer. 2006;118:802-11 pubmed
    HER-2/neu proto-oncogene is overexpressed in about one fourth of human breast cancers. AP-2 transcription factors bind to the HER-2/neu gene promoter and activate its expression...
  80. Pedersen K, Angelini P, Laos S, Bach Faig A, Cunningham M, Ferrer Ramón C, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol. 2009;29:3319-31 pubmed publisher
    b>HER2 is a tyrosine kinase receptor causally involved in cancer. A subgroup of breast cancer patients with particularly poor clinical outcomes expresses a heterogeneous collection of HER2 carboxy-terminal fragments (CTFs)...
  81. Brown M, Tsodikov A, Bauer K, Parise C, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008;112:737-47 pubmed publisher
    Breast cancers that are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (triple negative [TN]) have been associated with high-grade histology, aggressive clinical ..
  82. Lucs A, Muller W, Muthuswamy S. Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene. 2010;29:174-87 pubmed publisher
    ..Furthermore, we identify a novel function for Shc as a regulator of apoptosis and drug resistance in human mammary epithelial cells transformed by ErbB2. ..
  83. McAlpine J, Wiegand K, Vang R, Ronnett B, Adamiak A, Köbel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433 pubmed publisher
    ..We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian ..
  84. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006;103:7795-800 pubmed
    ..Establishing clinically relevant models of acquired resistance to ErbB2 kinase inhibitors will enhance therapeutic strategies to improve clinical outcomes for patients with ErbB2-overexpressing breast cancers. ..
  85. Alvarado D, Klein D, Lemmon M. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature. 2009;461:287-91 pubmed publisher
    The orphan receptor tyrosine kinase ErbB2 (also known as HER2 or Neu) transforms cells when overexpressed, and it is an important therapeutic target in human cancer...
  86. Pradeep C, Köstler W, Lauriola M, Granit R, Zhang F, Jacob Hirsch J, et al. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene. 2012;31:907-17 pubmed publisher
    ..of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene...
  87. Kostler W, Schwab B, Singer C, Neumann R, Rücklinger E, Brodowicz T, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:1618-24 pubmed
    The present pilot study was performed to elucidate whether early changes in serum Her-2/neu extracellular domain (ECD) levels during trastuzumab-based treatment would predict the clinical course of disease in patients with metastatic ..